TY - JOUR
T1 - Stimulatory effects of advanced glycation endproducts (AGEs) on fibronectin matrix assembly
AU - Pastino, Alexandra K.
AU - Greco, Todd M.
AU - Mathias, Rommel A.
AU - Cristea, Ileana M.
AU - Schwarzbauer, Jean E.
N1 - Funding Information:
The authors thank Charles G. Miller for helpful discussions and Greg M. Harris for help with microscopy. This research was funded by NIH grants R01 CA160611 and P41 EB001046 (to JES) and R01 GM114141 (to IMC). AKP was supported by NIH pre-doctoral training grant T32 GM007388.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Advanced glycation endproducts (AGEs) are a heterogeneous group of compounds that form via non-enzymatic glycation of proteins throughout our lifespan and at a higher rate in certain chronic diseases such as diabetes. AGEs contribute to the progression of fibrosis, in part by stimulating cellular pathways that affect gene expression. Long-lived ECM proteins are targets for non-enzymatic glycation but the question of whether the AGE-modified ECM leads to excess ECM accumulation and fibrosis remains unanswered. In this study, cellular changes due to AGE accretion in the ECM were investigated. Non-enzymatic glycation of proteins in a decellularized fibroblast ECM was achieved by incubating the ECM in a solution of methylglyoxal (MGO). Mass spectrometry of fibronectin (FN) isolated from the glycated matrix identified twenty-eight previously unidentified MGO-derived AGE modification sites including functional sites such as the RGD integrin-binding sequence. Mesangial cells grown on the glycated, decellularized matrix assembled increased amounts of FN matrix. Soluble AGE-modified bovine serum albumin (BSA) also stimulated FN matrix assembly and this effect was reduced by function-blocking antibodies against the receptor for AGE (RAGE). These results indicate that cells respond to AGEs by increasing matrix assembly and that RAGE is involved in this response. This raises the possibility that the accumulation of ECM during the progression of fibrosis may be enhanced by cell interactions with AGEs on a glycated ECM.
AB - Advanced glycation endproducts (AGEs) are a heterogeneous group of compounds that form via non-enzymatic glycation of proteins throughout our lifespan and at a higher rate in certain chronic diseases such as diabetes. AGEs contribute to the progression of fibrosis, in part by stimulating cellular pathways that affect gene expression. Long-lived ECM proteins are targets for non-enzymatic glycation but the question of whether the AGE-modified ECM leads to excess ECM accumulation and fibrosis remains unanswered. In this study, cellular changes due to AGE accretion in the ECM were investigated. Non-enzymatic glycation of proteins in a decellularized fibroblast ECM was achieved by incubating the ECM in a solution of methylglyoxal (MGO). Mass spectrometry of fibronectin (FN) isolated from the glycated matrix identified twenty-eight previously unidentified MGO-derived AGE modification sites including functional sites such as the RGD integrin-binding sequence. Mesangial cells grown on the glycated, decellularized matrix assembled increased amounts of FN matrix. Soluble AGE-modified bovine serum albumin (BSA) also stimulated FN matrix assembly and this effect was reduced by function-blocking antibodies against the receptor for AGE (RAGE). These results indicate that cells respond to AGEs by increasing matrix assembly and that RAGE is involved in this response. This raises the possibility that the accumulation of ECM during the progression of fibrosis may be enhanced by cell interactions with AGEs on a glycated ECM.
KW - Advanced glycation endproducts
KW - Extracellular matrix
KW - Fibronectin
KW - Mass spectrometry
KW - Non-enzymatic glycation
KW - RAGE
UR - http://www.scopus.com/inward/record.url?scp=84997545260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84997545260&partnerID=8YFLogxK
U2 - 10.1016/j.matbio.2016.07.003
DO - 10.1016/j.matbio.2016.07.003
M3 - Article
C2 - 27425255
AN - SCOPUS:84997545260
VL - 59
SP - 39
EP - 53
JO - Collagen and Related Research
JF - Collagen and Related Research
SN - 0945-053X
ER -